JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration ...
LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre ...
LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ...
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is ...
The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is tailored towards patients with moderate to severe ...
Verona Pharma Reports Q1 2025 Financial Results: $76.3 Million in Revenue Driven by Ohtuvayre® Sales
Verona Pharma plc reported total net revenue of $76.3 million for Q1 2025, driven primarily by significant sales of its product Ohtuvayre®, which generated $71.3 million, reflecting a 95% increase ...
Cost of Ohtuvayre Sales (Full Year 2024): $2.6 million Research and Development Costs (Q4 2024): $7.9 million Research and Development Costs (Full Year 2024): $44.6 million Selling, General and ...
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results